Abstract
People who inject drugs (PWID) account for the majority of new cases of hepatitis C virus (HCV) infection in Europe; however, HCV testing, and treatment for PWID remain suboptimal. With the advent of direct acting antivirals (DAAs) the World Health Organization (WHO) adopted a strategy to eliminate HCV as public health threat by 2030. To achieve this, key policies for PWID must be implemented and HCV continuum of care needs to be monitored. This study presents results of the first monitoring led by civil society that provide harm reduction services for PWID. In 2019, harm reduction civil society organizations representing focal points of Correlation-European Harm Reduction Network in 36 European countries were invited to complete a 27-item online survey on four strategic fields: use/impact of guidelines on HCV testing and treatment for PWID, availability/functioning of continuum of care, changes compared to the previous year and, the role of harm reduction services and non-governmental organizations (NGOs) of PWID. A descriptive analysis of the responses was undertaken. The response rate was 97.2%. Six countries reported having no guidelines on HCV treatment (17.1%). Twenty-three (65.7%) reported having treatment guidelines wit...Continue Reading
References
Sep 11, 2012·Journal of Hepatology·Knut Boe KiellandOlav Dalgard
Jul 3, 2013·Nature Reviews. Gastroenterology & Hepatology·Behzad HajarizadehGregory J Dore
Aug 2, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Geert RobaeysUNKNOWN International Network on Hepatitis in Substance Users
Aug 19, 2015·The International Journal on Drug Policy·Jason GrebelyUNKNOWN International Network for Hepatitis in Substance Users
Sep 29, 2015·World Journal of Hepatology·Rosa ZampinoEvangelista Sagnelli
Apr 30, 2016·The Cochrane Database of Systematic Reviews·Lucy PlattMatthew Hickman
Sep 18, 2016·The Lancet Infectious Diseases·Shevanthi NayagamTimothy B Hallett
Oct 14, 2016·AIDS and Behavior·Julia SmithTobias Alfvén
Aug 12, 2017·The International Journal on Drug Policy·Nick ScottMargaret E Hellard
Oct 28, 2017·The Lancet Global Health·Sarah LarneyLouisa Degenhardt
Apr 14, 2018·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, UNKNOWN European Association for the Study of the Liver
Jul 24, 2018·Addiction·Jason GrebelyLouisa Degenhardt
Oct 18, 2016·Hepatology, Medicine and Policy·Eberhard SchatzAstrid Leicht
Oct 28, 2018·Journal of Hepatology·Jenny IversenLisa Maher
Mar 12, 2019·Journal of Hepatology·Juan MacíasUNKNOWN HEPAVIR group from the Sociedad Andaluza de Enfermedades Infecciosas (SAEI) and the GEHEP group from the Sociedad Española d
May 11, 2019·Harm Reduction Journal·Mojca MaticicJeffrey V Lazarus
Sep 1, 2019·Journal of Internal Medicine·J V LazarusJ F Dillon
Jan 25, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M MatičičUNKNOWN ESCMID Study Group for Viral Hepatitis (ESGVH)
Jul 30, 2020·PloS One·Adam PalayewUNKNOWN Hep-CORE Study Group